GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company’s lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating p... GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company’s lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.89 | -8.21382007823 | 23.01 | 23.61 | 19.74 | 272511 | 20.61608917 | CS |
| 4 | -0.85 | -3.86891215294 | 21.97 | 25.9399 | 19.74 | 280808 | 22.32198693 | CS |
| 12 | 6.28 | 42.3180592992 | 14.84 | 25.9399 | 12.77 | 232993 | 20.22047291 | CS |
| 26 | 7.2 | 51.724137931 | 13.92 | 25.9399 | 12.04 | 305127 | 17.03086966 | CS |
| 52 | 7.6 | 56.2130177515 | 13.52 | 25.9399 | 11.32 | 299814 | 15.44556718 | CS |
| 156 | 8.66 | 69.5024077047 | 12.46 | 25.9399 | 5.05 | 191902 | 13.67956245 | CS |
| 260 | -0.88 | -4 | 22 | 30.43 | 5.05 | 149012 | 14.26267907 | CS |
EZ2
20分前
FlashySage44
26分前
FlashySage44
45分前
jay_tee
1時間前
doogdilinger
1時間前
joe_techi
1時間前
xoom
1時間前
gregcod
2時間前
rodeoup
2時間前
satter
3時間前
eagle8
3時間前
t1215s
3時間前
europa7
4時間前
barnstormer
5時間前
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。